Epigenetic Drug Discovery: Advancements, Challenges, and Applications in Precision Medicine
暫譯: 表觀遺傳藥物發現：精準醫療中的進展、挑戰與應用

這本書回顧了不斷發展的表觀遺傳學領域及其對藥物發現和精準醫療的影響。它還專注於調控基因的複雜機制以及表觀遺傳學對健康和疾病的影響。書中涵蓋了表觀遺傳機制的複雜性及其在癌症、自身免疫疾病、炎症狀況和神經退行性疾病等疾病中的角色。此外，它還探討了miRNA作為表觀遺傳藥物在治療癌症中的作用，以及計算機輔助的表觀遺傳藥物發現方法。這本書揭示了表觀遺傳藥物發現的潛力，包括對傳統醫學、海洋來源和OMICS技術的見解。此外，它還探討了腸道微生物群、益生菌和益生元在表觀遺傳治療方法中的相互作用。這本書專注於個人化醫療和藥物傳遞系統的最新進展，旨在為研究人員、臨床醫生和製藥專業人士提供探索表觀遺傳藥物發現和開發的資源。

主要特點
- 討論表觀遺傳機制在不同疾病中的影響及基於表觀遺傳的藥物發現。
- 回顧基於表觀遺傳機制的癌症、自身免疫疾病、神經退行性疾病和炎症疾病的靶向療法的發展。
- 強調基於表觀遺傳剖析的精準醫療和個人化療法的重要性。
- 探索人工智慧在設計新型表觀遺傳藥物傳遞系統中的應用。
- 提出計算機輔助和藥物發現工具在表觀遺傳藥物開發中的角色。

Dr M V N L Chaitanya, BPharm, M Pharm (Phytopharmacy and Phytomedicine), PhD (Pharmacognosy); Educationist and Researcher was born on November 10, 1982, in Rajahmundry (A.P.), India. He has 14 years of experience in industry, academia, and herbal research. He is currently working as a professor in the School of Pharmaceutical Sciences at the Lovely Professional University, Phagwara, Punjab, India. Dr Chaitanya is a well-recognized conceptualist in herbal medicine, anticancer drug discovery and development, crystal healing, and psychic reading at the Indian and African levels. He has a keen ability in laboratory drug discovery and development from herbs, weeds, algae, and mushrooms, with a proven ability in quality documentation. An awardee of various awards such as the INSA Visiting Scientist award for 2019, the AIMF award for 2019, the NFPS best professor award for 2022, and the DK International Best Researcher award for 2023. He is a life member of the Association of Pharmaceutical Teachers of India, the Indian Pharmaceutical Association, the Institute of Scholars (Insc), and the International Natural Product Sciences Task Force. He had visited three African countries as part of academic research to explore the phytochemicals in Indo-African plants against resistant diseases such as cancer, malaria, and tuberculosis. Dr Chaitanya's extensive body of work includes numerous research papers, peer-reviewed articles, books, and book chapters, and he holds multiple patents for his innovations.

Dr Trudi Collet, a biochemist, was awarded her PhD from the Queensland University of Technology in 2007. She worked as a postdoctoral fellow at the Queensland Institute of Medical Research and investigated novel serological markers for the differential diagnosis of inflammatory bowel disease. Since 2009, she has returned to QUT and is now the leader of the Innovative Medicines Group (IMG), which is based at the Kelvin Grove campus of the Queensland University of Technology. The IMG conducts research on the medicinal properties of Australian native plants. Using plant-derived bioactive compounds and extracts, the IMG evaluates the biological potential including bactericidal effects, the deadly ESKAPE pathogens; viricidal effects against members of the Flaviviridae family (Dengue, Zika and West Nile viruses); wound healing properties; antimicrobial effects against sexually transmitted diseases and novel pharmacotherapeutic targets for common neurological disorders.

Prof Jon Adams is Distinguished Professor of Public Health, Director of the Australian Research Centre in Complementary and Integrative Medicine (ARCCIM) and Deputy Head of School (Research) at the School of Public Health, UTS. Professor Adams was recently awarded a prestigious Fulbright Senior Scholarship (Fulbright Commission, 2019-2020). Professor Adams is the world-leading public health and health services researcher focused upon self-care, informal health care and traditional, complementary, integrative and indigenous medicine use and practice. Professor Adams' research program has attracted over $20.7M in competitive external funding to date including 23 Category 1 Grants (with 17 NHMRC and ARC grants). His extensive research program, conducted with many industry partners (>$10M in partnership funding), includes focus upon practice-based research networks (PBRNs), implementation science and translation research and mixed methods design. Professor Adams has authored over 560 peer-reviewed academic publications and is Chief Editor of eight international research books and author of over 70 book chapters with leading publishers.

Dr Kamal Dua is Associate Professor in the Discipline of Pharmacy at the University of Technology Sydney (UTS). Dr. Dua has been recognized and named one of Australia's Top 250 researchers in 2025 and 2024 in Research Magazine by "The Australian" in the research discipline of health and medical sciences and no. 1 research leader in the area of pharmacology and pharmacy (2025) and toxicology (2024), respectively. With over 17 years of research experience, he has specialized in drug delivery targeting inflammatory diseases. Additionally, he also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. His research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. His research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specializes in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

Dr Sachin Kumar Singh, a Professor at the School of Pharmaceutical Sciences, Lovely Professional University, India, earned his Master of Pharmacy in Pharmaceutical Analysis from J.S.S. College of Pharmacy, Ooty, Tamil Nadu, India and earned his PhD in Pharmaceutical Sciences from Karpagam University, Coimbatore, India. He has completed one DST-SERB funded project on development of SNEDDS of Polypeptide-k for treatment of diabetes mellitus. Dr. Singh has published more than 200 research papers with cumulative impact of 400 and co-authored 10 book chapters. He has two granted Indian patents and two granted Australian patents. In January 2020, he received Dr. B.C. Deb memorial award for popularization of science by Indian Science Congress Association at 107th Indian Science Congress held at UAS Bengaluru. He is the first recipient from the field of Pharmaceutical Sciences to receive this award. He is also a recipient of 2014 Bharat Shiksha Ratan Award given by Global Society for Health and Educational Growth, Delhi, India. His core area is improving oral bioavailability of drugs exhibiting poor water solubility characteristics using various formulation approaches including nanotechnology, complexation, solid dispersion, and liquisolid technology.

Dr M V N L Chaitanya, BPharm, M Pharm (植物藥學與植物醫學), PhD (藥用植物學); 教育家與研究者於1982年11月10日出生於印度安得拉邦的拉賈曼德里。他在產業、學術和草藥研究方面擁有14年的經驗。目前，他在印度旁遮普邦的Lovely Professional University藥學院擔任教授。Dr Chaitanya在草藥醫學、抗癌藥物發現與開發、晶體療法和靈性閱讀方面是廣受認可的概念家。他在從草藥、雜草、藻類和蘑菇中進行實驗室藥物發現與開發方面具有敏銳的能力，並在質量文件方面有著良好的表現。他曾獲得多項獎項，包括2019年的INSA訪問科學家獎、2019年的AIMF獎、2022年的NFPS最佳教授獎以及2023年的DK國際最佳研究者獎。他是印度藥學教師協會、印度藥學協會、學者研究所（Insc）和國際天然產品科學工作組的終身會員。他曾作為學術研究的一部分，訪問三個非洲國家，探索印非植物中的植物化學物質，以對抗癌症、瘧疾和結核病等抗藥性疾病。Dr Chaitanya的廣泛研究成果包括多篇研究論文、同行評審文章、書籍和書籍章節，並擁有多項創新專利。

Dr Trudi Collet是一位生物化學家，於2007年獲得昆士蘭科技大學的博士學位。她曾在昆士蘭醫學研究所擔任博士後研究員，研究用於炎症性腸病的差異診斷的新型血清標記。自2009年以來，她回到昆士蘭科技大學，現在是位於昆士蘭科技大學凱爾文格羅夫校區的創新藥物小組（IMG）的負責人。IMG進行有關澳大利亞本土植物的藥用特性的研究。IMG利用植物衍生的生物活性化合物和提取物，評估其生物潛力，包括對致命的ESKAPE病原體的殺菌效果；對Flaviviridae家族成員（登革熱、茲卡病毒和西尼羅病毒）的病毒殺滅效果；傷口癒合特性；對性傳播疾病的抗微生物效果以及針對常見神經疾病的新型藥物治療目標。

Prof Jon Adams是公共衛生特聘教授，澳大利亞互補與整合醫學研究中心（ARCCIM）主任及悉尼科技大學公共衛生學院（UTS）研究副院長。Adams教授最近獲得了2019-2020年富布賴特高級獎學金（Fulbright Commission）。Adams教授是全球領先的公共衛生和健康服務研究者，專注於自我照護、非正式醫療以及傳統、互補、整合和土著醫學的使用與實踐。Adams教授的研究計劃迄今已吸引超過2070萬美元的競爭性外部資金，包括23項類別1資助（其中17項為NHMRC和ARC資助）。他的廣泛研究計劃與許多產業夥伴合作（超過1000萬美元的合作資金），包括專注於基於實踐的研究網絡（PBRNs）、實施科學和轉化研究及混合方法設計。Adams教授已發表超過560篇同行評審的學術出版物，並擔任八本國際研究書籍的主編，以及與主要出版商共同撰寫超過70章書籍。

Dr Kamal Dua是悉尼科技大學（UTS）藥學學科的副教授。Dua博士在2024年和2025年被《澳大利亞》雜誌評選為澳大利亞前250名研究者，並在藥理學和藥學領域分別被評為2025年和2024年的研究領導者。在超過17年的研究經驗中，他專注於針對炎症性疾病的藥物傳遞。此外，他還在Woolcock醫學研究所領導藥物傳遞研究。在這個角色中，他專注於推進研究項目中確定的目標，以開發創新配方，邁出臨床轉化的第一步。他的研究涵蓋兩個互補領域：藥物傳遞和免疫學。他的工作探討這些學科如何相互受益，促進社區更長壽和更健康的生活。他對協同作用的承諾在他在知名期刊上的廣泛出版記錄中得以體現。他的研究興趣集中在利用調節關鍵調節因子（如白介素和微小RNA）的藥物潛力。他還專注於開發新型有效的藥物傳遞配方，以管理慢性氣道疾病和癌症中的炎症。

Dr Sachin Kumar Singh是印度Lovely Professional University藥學院的教授，他在印度泰米爾納德邦的J.S.S.藥學院獲得藥學碩士學位，並在印度科印巴多的Karpagam大學獲得藥學博士學位。他完成了一個DST-SERB資助的項目，開發用於治療糖尿病的Polypeptide-k的SNEDDS。Singh博士已發表超過200篇研究論文，累計影響因子達400，並共同撰寫10章書籍。他擁有兩項已授予的印度專利和兩項已授予的澳大利亞專利。2020年1月，他在第107屆印度科學大會上獲得印度科學大會頒發的Dr. B.C. Deb紀念獎，以推廣科學。他是第一位來自藥學領域的獲獎者。他還是2014年由全球健康與教育增長協會頒發的Bharat Shiksha Ratan獎的獲得者。他的核心領域是利用各種配方方法（包括納米技術、複合化、固體分散和液體固體技術）改善顯示出差的水溶性特徵的藥物的口服生物利用度。